Clinical Trial Update: IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis [Phase 1]

View source ↗

Summary

Phase 1 trial of IDP-023 g-NK cells plus ocrelizumab for progressive multiple sclerosis has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Progressive Multiple Sclerosis

Drugs mentioned

• IDP-023 g-NK Cells (g-NK cells)
• Ocrelizumab (ocrelizumab)

Snippet

Sponsor: Indapta Therapeutics, INC. | Conditions: Multiple Sclerosis, Primary Progressive Multiple Sclerosis (PPMS) | Phase 1 | Status: SUSPENDED